StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
1195
This month
14
This week
7
This year
40
Today
1
Yesterday
4
Publishing Date
2023 - 12 - 11
5
2023 - 07 - 10
5
2023 - 06 - 21
5
2023 - 05 - 30
5
2023 - 04 - 26
5
2022 - 12 - 21
5
2022 - 11 - 10
7
2022 - 10 - 27
5
2022 - 07 - 28
5
2022 - 07 - 06
6
2022 - 05 - 31
8
2022 - 05 - 26
7
2022 - 05 - 23
10
2022 - 05 - 05
7
2022 - 05 - 03
7
2022 - 04 - 25
7
2022 - 04 - 20
5
2022 - 03 - 31
6
2022 - 03 - 15
6
2022 - 03 - 14
7
2022 - 02 - 28
6
2022 - 02 - 17
4
2022 - 01 - 24
5
2022 - 01 - 20
6
2022 - 01 - 18
10
2022 - 01 - 13
5
2022 - 01 - 11
4
2022 - 01 - 06
4
2022 - 01 - 04
4
2021 - 12 - 20
4
2021 - 12 - 13
14
2021 - 12 - 06
8
2021 - 12 - 02
4
2021 - 12 - 01
5
2021 - 11 - 29
5
2021 - 11 - 15
9
2021 - 11 - 08
5
2021 - 10 - 21
6
2021 - 10 - 04
7
2021 - 09 - 27
6
2021 - 09 - 20
5
2021 - 09 - 13
4
2021 - 08 - 09
4
2021 - 07 - 28
5
2021 - 07 - 22
5
2021 - 07 - 19
4
2021 - 06 - 30
7
2021 - 06 - 28
5
2021 - 06 - 23
5
2021 - 06 - 21
5
2021 - 06 - 11
7
2021 - 06 - 08
4
2021 - 06 - 07
6
2021 - 06 - 03
5
2021 - 06 - 01
4
2021 - 05 - 10
4
2021 - 04 - 12
5
2021 - 04 - 06
4
2020 - 12 - 15
6
2020 - 12 - 10
4
Sector
Commercial services
9
Communications
9
Consumer non-durables
2
Consumer services
3
Distribution services
7
Finance
5
Health services
15
Health technology
924
Industrial services
1
Manufacturing
75
N/a
30
Process industries
4
Producer manufacturing
2
Professional, scientific, and technical services
48
Technology services
3
Transportation and warehousing
5
Wholesale trade
6
Tags
Alliances
104
Als
190
Alzheimer's
104
Alzheimer’s
151
Antibody
100
Application
135
Approval
167
Biopharma
169
Biotech
133
Biotech-bay
105
Biotech-beach
115
Cancer
788
Cell
122
China
108
Clearance
115
Clinical trials
130
Clinical-trials-phase-i
219
Clinical-trials-phase-ii
1195
Clinical-trials-phase-iii
902
Collaboration
137
Conference
350
Covid
315
Covid-19
237
Deadline
140
Disease
540
Drug
219
Enroll
318
Europe
134
Events
122
Fda
374
First
97
Genetown
143
Growth
146
Iot
125
Meeting
231
N/a
4276
Ongoing
249
Pharm-country
156
Pharma
157
Pharmaceuticals
256
Phase 1
750
Phase 1b
124
Phase 2
1215
Phase 2b
438
Phase 3
854
Positive
947
Potential
113
Presentation
218
Publication
115
Research
595
Results
1020
Study
296
Therapeutics
876
Therapy
361
Topline
407
Treatment
1036
Trial
6819
Trials
569
Update
148
Vaccine
283
Entities
Abvc biopharma inc
6
Adamis pharmaceuticals corporation
5
Aldeyra therapeutics, inc.
9
Algernon pharmaceuticals inc.
6
Alzamend neuro inc
7
Amgen inc.
6
Amylyx pharmaceuticals, inc.
6
Anavex life sciences corp.
6
Annovis bio, inc.
7
Aptinyx inc.
6
Arcturus therapeutics holdings inc.
6
Arrowhead pharmaceuticals, inc.
17
Astrazeneca plc
7
Axcella health inc.
6
Beigene, ltd.
9
Biogen inc.
5
Biovie inc.
5
Bristol-myers squibb company
15
Can-fite biopharma ltd
7
Cardiff oncology, inc.
5
Clearside biomedical, inc.
7
Clene inc
7
Curis, inc.
6
Cybin inc
11
Diamedica therapeutics inc.
6
Dynavax technologies corporation
5
Edesa biotech, inc.
6
Eli lilly and company
18
First wave biopharma, inc.
9
Fortress biotech, inc.
7
Galecto, inc.
5
Gilead sciences, inc.
7
Gritstone oncology, inc.
5
Horizon therapeutics public limited company
7
I-mab
13
Ideaya biosciences, inc.
5
Immutep limited
10
Incyte corporation
6
Infinity pharmaceuticals, inc.
6
Johnson & johnson
54
Kintara therapeutics, inc.
7
Lineage cell therapeutics, inc.
7
Maia biotechnology, inc.
11
Mediwound ltd.
11
Merck & company, inc.
9
Moderna, inc.
8
Moleculin biotech, inc.
7
Mymd pharmaceuticals inc
6
Orange
9
Pds biotechnology corporation
6
Pfizer, inc.
9
Protagonist therapeutics, inc.
7
Redhill biopharma ltd.
10
Regenxbio inc.
7
Sanofi
51
Scholar rock holding corporation
6
Sorrento therapeutics, inc.
7
Takeda pharmaceutical company limited
10
Vertex pharmaceuticals incorporated
9
Virios therapeutics inc
6
Symbols
ABVC
6
ADMP
5
AGNPF
6
ALDX
9
ALZN
7
AMGN
6
AMLX
6
ANVS
7
APTX
6
ARCT
6
ARWR
17
AVXL
6
AXLA
6
AZN
7
BGNE
9
BIIB
5
BIVI
5
BMY
15
CANF
7
CLNN
7
CLSD
7
CRDF
5
CRIS
6
CYBN
11
DMAC
6
DVAX
5
EDSA
6
FBIO
7
FNCTF
9
FWBI
9
GILD
7
GLTO
5
GRTS
5
HZNP
7
IMAB
13
IMMP
10
INCY
6
INFI
6
JNJ
54
KTRA
7
LCTX
7
LLY
18
MAIA
11
MBRX
7
MDWD
11
MRK
9
MRNA
8
MYMD
6
PDSB
6
PFE
9
PTGX
7
RDHL
10
RGNX
7
SNY
51
SNYNF
42
SRNE
7
SRRK
6
TAK
10
VIRI
6
VRTX
9
Exchanges
Amex
34
Nasdaq
1052
Nyse
153
Crawled Date
2023 - 07 - 10
5
2023 - 06 - 21
5
2023 - 05 - 30
5
2023 - 04 - 26
5
2022 - 12 - 21
5
2022 - 11 - 10
7
2022 - 10 - 27
5
2022 - 07 - 28
5
2022 - 07 - 07
5
2022 - 05 - 31
8
2022 - 05 - 27
5
2022 - 05 - 23
10
2022 - 05 - 05
7
2022 - 05 - 04
6
2022 - 05 - 03
5
2022 - 04 - 25
7
2022 - 04 - 20
5
2022 - 03 - 31
6
2022 - 03 - 15
6
2022 - 03 - 14
7
2022 - 02 - 28
6
2022 - 02 - 17
4
2022 - 01 - 24
4
2022 - 01 - 20
6
2022 - 01 - 19
5
2022 - 01 - 18
8
2022 - 01 - 13
5
2022 - 01 - 11
4
2022 - 01 - 04
4
2021 - 12 - 20
4
2021 - 12 - 13
14
2021 - 12 - 06
8
2021 - 12 - 02
4
2021 - 12 - 01
5
2021 - 11 - 29
5
2021 - 11 - 15
9
2021 - 11 - 08
5
2021 - 10 - 21
6
2021 - 10 - 04
7
2021 - 09 - 27
6
2021 - 09 - 20
5
2021 - 09 - 13
4
2021 - 08 - 09
4
2021 - 07 - 28
5
2021 - 07 - 22
5
2021 - 07 - 19
4
2021 - 06 - 30
7
2021 - 06 - 28
5
2021 - 06 - 23
5
2021 - 06 - 21
5
2021 - 06 - 11
7
2021 - 06 - 09
4
2021 - 06 - 07
6
2021 - 06 - 03
5
2021 - 06 - 01
4
2021 - 05 - 10
4
2021 - 04 - 12
5
2021 - 04 - 06
4
2020 - 12 - 15
6
2020 - 12 - 10
4
Crawled Time
00:00
30
00:20
3
01:00
8
05:00
13
06:00
8
07:00
2
08:00
7
09:00
7
10:00
9
11:00
30
12:00
153
12:15
11
12:20
17
12:30
10
12:39
1
13:00
133
13:15
13
13:20
27
13:30
43
13:35
4
14:00
163
14:15
8
14:20
16
14:23
1
14:30
19
15:00
107
15:15
2
15:20
4
15:30
23
16:00
50
17:00
45
18:00
46
19:00
27
20:00
27
21:00
34
22:00
58
23:00
36
Source
www.biospace.com
1195
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
tags :
Clinical-trials-phase-ii
save search
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published:
2024-04-18
(Crawled : 12:00)
- biospace.com/
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
|
-4.21%
|
O:
10.02%
H:
0.0%
C:
0.0%
bb-301
first
positive
biopharma
for
trial
opmd
study
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Published:
2024-04-17
(Crawled : 22:00)
- biospace.com/
EOLS
|
$11.56
-0.69%
-0.69%
340K
|
Health Technology
|
-1.49%
|
O:
-1.49%
H:
0.0%
C:
0.0%
jeuveau
publication
for
study
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published:
2024-04-17
(Crawled : 22:00)
- biospace.com/
DMAC
|
$2.45
-5.77%
-6.12%
17K
|
Health Technology
|
4.43%
|
O:
4.43%
H:
0.0%
C:
0.0%
dm199
first
stroke
treatment
for
trial
therapeutics
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published:
2024-04-17
(Crawled : 12:00)
- biospace.com/
SAGE
|
$13.03
3.66%
3.53%
1.8M
|
Health Technology
|
-17.57%
|
O:
-15.02%
H:
3.55%
C:
-3.01%
sage-718
disease
treatment
topline
parkinson’s
therapeutics
results
study
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Published:
2024-04-16
(Crawled : 00:00)
- biospace.com/
AMGN
|
$262.77
-0.49%
-0.49%
2M
|
Health Technology
|
0.54%
|
O:
0.41%
H:
0.0%
C:
0.0%
tezspire
copd
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
Published:
2024-04-16
(Crawled : 14:00)
- biospace.com/
PTCHF
|
$2.78
19.97%
560
|
n/a
|
Email alert
Add to watchlist
lyt-100
fibrosis
trial
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Published:
2024-04-15
(Crawled : 12:00)
- biospace.com/
JNJ
|
News
|
$145.74
0.67%
0.0%
9.3M
|
Health Technology
|
-2.32%
|
O:
-0.04%
H:
0.0%
C:
0.0%
avb-101
first
dementia
for
trial
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Published:
2024-04-10
(Crawled : 14:00)
- biospace.com/
AMLX
|
$1.97
-1.5%
-1.52%
1M
|
|
-24.72%
|
O:
-2.62%
H:
1.54%
C:
-5.38%
amx0035
control
pancreatic
ongoing
pharmaceuticals
trial
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published:
2024-04-04
(Crawled : 11:00)
- biospace.com/
ACHL
|
$0.795
-2.39%
-2.45%
190K
|
Manufacturing
|
-31.44%
|
O:
-16.22%
H:
0.99%
C:
-7.89%
first
melanoma
update
therapeutics
advanced
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Published:
2024-04-03
(Crawled : 19:00)
- biospace.com/
MRNA
S
|
$102.015
-1.38%
-1.4%
1.7M
|
Health Technology
|
-0.16%
|
O:
-0.59%
H:
2.09%
C:
-1.74%
rna-3927
mrna
therapy
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Published:
2024-04-03
(Crawled : 13:00)
- biospace.com/
MRK
|
$125.23
-0.11%
0.0%
6M
|
Health Technology
|
-3.82%
|
O:
0.13%
H:
0.0%
C:
0.0%
cancer
trial
initiated
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Published:
2024-04-03
(Crawled : 13:00)
- biospace.com/
ALGS
|
$0.781
-0.76%
-0.77%
240K
|
Health Technology
|
-14.62%
|
O:
2.25%
H:
4.0%
C:
1.0%
alg-0550
first
therapeutics
study
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published:
2024-04-01
(Crawled : 17:00)
- biospace.com/
VRTX
|
News
|
$393.51
0.1%
0.1%
950K
|
Health Technology
|
-5.96%
|
O:
0.56%
H:
0.0%
C:
0.0%
vx-147
disease
kidney
treatment
trial
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Published:
2024-04-01
(Crawled : 17:00)
- biospace.com/
NTRA
S
|
$87.19
-3.48%
-3.6%
1.1M
|
Health Services
|
-1.24%
|
O:
-0.6%
H:
2.8%
C:
2.25%
cancer
trials
trial
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Published:
2024-03-27
(Crawled : 23:00)
- biospace.com/
REGN
|
$893.66
-0.84%
-0.84%
450K
|
Health Technology
|
-6.47%
|
O:
0.78%
H:
0.4%
C:
-0.49%
ren026
fda
study
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Published:
2024-03-15
(Crawled : 12:30)
- biospace.com/
CYBN
|
News
|
$0.3699
-1.47%
1.05%
1.7M
|
n/a
|
-11.52%
|
O:
1.59%
H:
7.78%
C:
5.55%
cyb004
study
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published:
2024-03-14
(Crawled : 12:30)
- biospace.com/
CYBN
|
News
|
$0.3699
-1.47%
1.05%
1.7M
|
n/a
|
-9.62%
|
O:
7.14%
H:
5.53%
C:
-4.67%
cyb003
fda
positive
meeting
program
design
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Published:
2024-03-08
(Crawled : 14:30)
- biospace.com/
ARWR
|
$22.62
0.4%
0.4%
1.3M
|
Health Technology
|
-28.7%
|
O:
1.14%
H:
5.63%
C:
-0.39%
treatment
pharmaceuticals
study
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
Published:
2024-03-06
(Crawled : 14:30)
- biospace.com/
MAIA
|
$1.96
-1.01%
0.0%
68K
|
|
33.78%
|
O:
9.46%
H:
4.94%
C:
-9.26%
lung
cancer
cell
treatment
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
Published:
2024-03-06
(Crawled : 14:30)
- biospace.com/
DTIL
|
$10.77
-6.43%
-6.87%
71K
|
Health Technology
|
5.41%
|
O:
1.56%
H:
3.55%
C:
0.81%
precision
approval
arcus
program
trial
← Previous
1
2
3
4
5
6
7
8
9
…
59
60
Next →
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.